Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024)
Historic Cost of Revenue for Avalo Therapeutics (AVTX) over the last 8 years, with Q3 2024 value amounting to $714000.0.
- Avalo Therapeutics' Cost of Revenue rose 18906.88% to $714000.0 in Q3 2024 from the same period last year, while for Jun 2025 it was $1.1 million, marking a year-over-year increase of 15322.94%. This contributed to the annual value of $1.3 million for FY2023, which is 6260.92% down from last year.
- According to the latest figures from Q3 2024, Avalo Therapeutics' Cost of Revenue is $714000.0, which was up 18906.88% from $343000.0 recorded in Q2 2024.
- Avalo Therapeutics' Cost of Revenue's 5-year high stood at $1.6 million during Q2 2022, with a 5-year trough of -$221000.0 in Q4 2023.
- For the 5-year period, Avalo Therapeutics' Cost of Revenue averaged around $528842.1, with its median value being $549000.0 (2020).
- In the last 5 years, Avalo Therapeutics' Cost of Revenue surged by 178795.18% in 2022 and then plummeted by 13564.52% in 2023.
- Avalo Therapeutics' Cost of Revenue (Quarter) stood at $549000.0 in 2020, then dropped by 22.77% to $424000.0 in 2021, then skyrocketed by 46.23% to $620000.0 in 2022, then tumbled by 135.65% to -$221000.0 in 2023, then soared by 423.08% to $714000.0 in 2024.
- Its Cost of Revenue stands at $714000.0 for Q3 2024, versus $343000.0 for Q2 2024 and $80000.0 for Q1 2024.